Baker Botts (Brussels)

Catriona Hatton

Baker Botts (Brussels)
Managing Partner

Catriona Hatton is the partner in charge of the firm’s Brussels office and co-chair of the firm’s global antitrust and competition law group. She is well known for her work in EU and international merger control, representing clients in some of the largest most complex deals in the market, as well as in antitrust investigations and compliance matters. She advises clients in a number of sectors, including pharmaceuticals, mining, media and entertainment, automotive, chemicals and energy. Catriona is recommended in Chambers Europe (2019) as a business-oriented practitioner. Clients describe her as ‘exceptionally pragmatic and sensitive to the commercial balances that (they) need to achieve, with the ability to communicate in a non-confrontational way’. She is also recommended in Chambers Global, where she is particularly praised for her commercial acumen and her work in international merger control. Catriona was named as a Global Elite Thought Leader by Who’s Who Legal, 2020, listed as a Leading Individual in Antitrust by Legal 500, 2020 and was named ‘Lawyer of the Year’ in EU law (Brussels) by Best Lawyers (2018). Catriona is an Officer of the International Bar Association’s Antitrust Section.


Linked authors

Baker Botts (New York)
Baker Botts (London)
Baker Botts (Washington)
Baker Botts (Washington)
Baker Botts (Washington)


Catriona Hatton (Baker Botts)
Catriona Hatton 19 May 2022 London
Catriona Hatton (Baker Botts)
Catriona Hatton 26 September 2019 Brussels
Catriona Hatton (Baker Botts)
Catriona Hatton 20 September 2018 Brussels
Catriona Hatton (Baker Botts)
Catriona Hatton 7 September 2017 Bruxelles
Catriona Hatton - Global Antitrust Hot Topics, 8 September 2016
Catriona Hatton 8 September 2016 Bruxelles
Catriona Hatton
Catriona Hatton 17 September 2015 Bruxelles


33310 Bulletin

Catriona Hatton, Matthew Levitt, Dina Jubrail, Stuart Blythe, Nigel Stacey, Derek Jones The UK Government proposes screening powers for certain deals on national security grounds


This week, the UK Government announced new draft powers under the National Security and Investment Bill (the ‘Bill’) to screen certain deals on national security grounds. The proposals apply to takeovers and investments (including minority share acquisitions) by foreign buyers in a wide range of (...)

Maureen Ohlhausen, Catriona Hatton, Adam Dawson, Paul Lugard, Matthew Levitt, Dina Jubrail The EU Commission launches consultations on ex-ante competition enforcement in platform-based and other industries


Recently, the European Commission (“EC”) launched two major public consultations for new legislative tools intended to step up antitrust enforcement in digital and other markets. One consultation relates to a new competition enforcement tool that would allow the EC to pro-actively intervene in (...)

Catriona Hatton, Paul Lugard, Daniel Vasbeck The EU Court of Justice clarifies for the first time when patent settlement agreements restricting a generic pharmaceutical company’s ability to enter the market infringes the EU antitrust rules (Generics - UK / GlaxoSmithKline / Actavis / Xellia Pharmaceuticals / Merck / Alpharma)


In a major judgment handed down on 30 January 2020 in Generics (UK) and Others, the EU Court of Justice (the Court) – the EU’s highest court – clarified for the first time the analytical framework for assessing when patent settlement agreements that restrict a generic pharmaceutical company’s (...)

Catriona Hatton, Sofia Doudountsaki The EU Commission imposes interim measures for the first time in 18 years making the company cease and desist until the end of the investigation (Broadcom)


For the first time in 18 years, the European Commission (“Commission”) has imposed interim measures on a company, ordering it to cease and desist certain practices pending the outcome of its antitrust investigation (or for a period of 3 years if the investigation is not concluded earlier). The (...)

Stephen Weissman, Catriona Hatton, John Taladay The US District Court of Delaware spotlights the importance of antitrust risk-shifting provisions in merger agreements in the pharmaceutical sector (Akorn / Fresenius)


As counsel involved in negotiating mergers, acquisitions, or other transactions know, provisions that allocate antitrust risk between buyer and seller, or between joint venture (JV) partners, are a common feature of merger and JV agreements. Such provisions are increasingly important in today’s (...)

Nathan Chubb, Catriona Hatton, Michael J. Perry, Stephen Weissman The US Government Accountability Office publishes the results of its study into the prescription drug industry


Prior to the year-end holiday season, the United States Government Accountability Office (“GAO”) released the results of its long-awaited study into the prescription drug industry’s “Profits, Research and Development Spending, and Merger and Acquisition Deals.” The report responds to Congressional (...)

Catriona Hatton, Daniel Vasbeck The German Parliament adopts a reform of the national competition act and introduces an additional merger control threshold based on the value of the transaction


On 31 March 2017, the German Parliament adopted a reform of the country’s competition act (ARC). Among other amendments, it introduces an additional merger control threshold based on the value of the transaction. This amendment was prompted by a perceived enforcement gap in the current law: (...)

Catriona Hatton, Satu-Anneli Kauranen The Irish Competition Authority settles an alleged price-fixing dispute in the health sector relating to medical examination reports to life insurance companies (Irish Medical Organisation - IMO)


Introduction On 28 May 2007, the Irish Competition Authority announced that it had concluded a settlement agreement with the Irish Medical Organisation (IMO) on 25 May 2007. The settlement concerns an alleged price-fixing by the IMO in relation to the provision of Private Medical Attendant (...)

Aymeric Dumas-Eymard, Catriona Hatton The Irish Public Prosecutor brings criminal charges against a businessman alleged to have taken part in a price fixing agreement (IFDA / Ford)


Facts On 19 April 2006, the Director of Public Prosecutions for Ireland brought criminal charges against a businessman alleged to have aided members of the IFDA (Irish Ford Dealers Association) in fixing the prices of Ford vehicles on the Irish market. Few details have emerged concerning the (...)


Send a message